GILD - Gilead Sciences, Inc.
| Previous Close | 67.60 |
| Open | 67.59 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 1000 |
| Day's Range | 67.34 - 68.49 |
| 52 Week Range | 63.76 - 89.54 |
| Volume | 5,422,767 |
| Avg. Volume | 7,295,113 |
| Market Cap | 88.444B |
| Beta | 1.35 |
| PE Ratio (TTM) | 25.87 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 2.28 (3.49%) |
| Ex-Dividend Date | 2018-06-14 |
| 1y Target Est | N/A |
- InvestorPlace•2 days ago
FDA Shame List: 40 Drug Makers That Try to Block Generic Drugs
The Food and Drug Administration (FDA) announced a shame list of companies that try to block generic drugs in order to ramp up profits.
- Reuters•3 days ago
EU warns of possible birth defect link to GSK's HIV drug
Europe's medicines regulator said it was assessing evidence that GlaxoSmithKline's successful HIV drug dolutegravir might be linked to birth defects, adding it should not be prescribed to women seeking to become pregnant. Friday's move by the European Medicines Agency follows preliminary data from a study in Botswana which found four cases of neural tube defects (NTDs), such as spina bifida, in babies born to mothers who became pregnant while taking the drug. Dolutegravir is a so-called integrase inhibitor found in the branded medicines Tivicay and Triumeq, which are sold by GSK's majority-owned ViiV Healthcare unit.
- Investor's Business Daily•3 days ago
The FDA Is Trying To 'Shame' Celgene, Gilead — Here's Why It Won't Work
Celgene toppled to a four-year low Thursday after it appeared on a list from the FDA attempting to "shame" drugmakers working to block generic competition.
- American City Business Journals•3 days ago
Gilead, BioMarin among Bay Area drug makers shamed by FDA in generics 'gaming' list
Opening another front in President Donald Trump's war on drug prices, the FDA releases a list of companies "gaming" the system to delay lower-priced generics from getting to market.
- Motley Fool•4 days ago
Sangamo Therapeutics Stock History
After decades of research into gene editing, this biotech company could be on the cusp of developing game-changing new treatments for rare diseases.
Market Realist•4 days agoTaking Stock of Gilead Sciences’ Key Developments
During the first quarter, Gilead Sciences (GILD) entered into a scientific collaboration with Verily Life Sciences to identify and better understand the immunological basis of three common, serious inflammatory diseases—rheumatoid arthritis, inflammatory bowel disease, and lupus-related diseases—by making use of Verily’s Immunoscape platform.
- Reuters•4 days ago
FDA names drugmakers likely blocking access to branded drug samples
The U.S. Food and Drug Administration on Thursday named drugmakers including Celgene Corp, Mylan NV, Gilead Sciences and Novartis AG for potentially blocking access to samples of their products to delay generic competition. Generic drugmakers may not be able to develop alternatives without access to samples of branded products, the FDA said. The regulator said it had heard of some brand companies adopting tactics to make it hard for the generic companies to purchase branded drugs at a fair value and in open market.
- Motley Fool•4 days ago
3 High-Yield Stocks With Virtual Monopolies
This trio of high-yield stocks offers dividend investors a lock on key markets with virtual monopolies driving big dividend payments.
- Market Realist•4 days ago
Gilead Sciences’ Cash Flows, Valuations, and Price Performance
Gilead Sciences (GILD) stock has corrected 9.6% since the start of 2018 to close at $66.99 on May 15. In comparison, Johnson & Johnson (JNJ), Pfizer (PFE), and Merck & Co. (MRK) have returned -9.5%, -2.1%, and 5.3%, respectively.
- Market Realist•4 days ago
A Look at Gilead Sciences’ Financial Performance
Gilead Sciences’ (GILD) total revenues decreased from $6.5 billion in Q1 2017 to $5.1 billion in Q1 2018, primarily due to lower product sales. The company earns a small part of its revenues from royalty, contract, and other sources. While product sales were $6.3 billion in Q1 2017 and $5 billion in Q1 2018, royalty, contract, and other revenues were $128 million in Q1 2017 and $87 million in Q1 2018.
Market Realist•4 days agoGilead Sciences’ Product Performance: A Mixed Bag in Q1 2018
In the first quarter, Gilead Sciences’ (GILD) total product sales decreased to $5 billion from $6.3 billion in the first quarter of 2017. For fiscal 2018 and fiscal 2019, it’s expected to report total revenues of $20.8 billion and $21.1 billion, respectively.
Market Realist•4 days agoGilead Sciences Stock: How Much Upside Do Analysts Expect?
Gilead Sciences (GILD) is a research-based biopharmaceutical company focused on discovering, developing, and bringing to market innovative medicines for life-threatening diseases. Gilead released its first-quarter earnings on May 4. Of the 26 analysts covering Gilead Sciences stock in May, 16 of them have given the stock a “buy” or higher rating, and ten have given it a “hold.” The mean rating for the stock is 2.2 with a target price of $85.81, which implies an upside potential of 27.2% over its closing price of $66.99 on May 15.
- Investor's Business Daily•5 days ago
Breakout Watch: Biotech Stock With 172% Growth Enters Buy Zone
Leading biotech stock and IBD 50 member Ligand Pharmaceuticals is in a buy zone after reporting 172% earnings growth.
- MarketWatch•6 days ago
Why Trump’s drug-price pitch makes no sense
Donald Trump’s speech on drug prices on Friday was no surprise — it was his usual mishmash of pseudo-populist nonsense, obscuring the standard-issue corporatist Republican agenda he reverts to when he knows nothing, which is most of the time. The speech abandoned one of the few more-or-less populist campaign promises the president made in 2016 — to have Medicare begin negotiating over drug prices, reversing a law his party passed specifically to maximize drug-company profits.
- CNBC•10 days ago
Cramer says it's 'very hard to put a price on' lifesaving drugs
President Trump on Friday is set to release a plan aimed at cutting prescription drug costs. But Jim Cramer argues some drugs may be worth it.
- CNBC•10 days ago
Cramer says it's 'very hard to put a price on' lifesaving drugs
President Trump on Friday is set to release a plan aimed at cutting prescription drug costs. But Jim Cramer argues some drugs may be worth it.
- Investopedia•11 days ago
Gilead May Rebound By 12% Short Term
Gilead Sciences Inc. ( GILD) shares appear poised to rebound by about 12%, taking the stock back to around $72. Revenue missed estimates by nearly 6%, coming in at $5.088 billion, while earnings missed estimates by 11.25% at $1.48, resulting in shares plunging by 9.5%. The chart below shows that Gilead shares have reached a critical support level around $64 and has so far been able to remain above it.
Market Realist•11 days agoAnalysts’ Recommendations for Regeneron Pharmaceuticals in May
In April 2018, the FDA accepted for priority review Regeneron Pharmaceuticals (REGN) and Sanofi’s (SNY) Biologics License Application (or BLA) for cemiplimab for the treatment of individuals with metastatic CSCC (cutaneous squamous cell carcinoma) or individuals with locally advanced CSCC who cannot be treated with surgery. In September 2017, the FDA granted cemiplimab Breakthrough Therapy designation status for the treatment of metastatic CSCC. The FDA provided a Prescription Drug User Fee Act action date of October 28, 2018.
- Motley Fool•12 days ago
Why Bristol-Myers Squibb Stock Crashed in April
The company's stock hasn't been this cheap in years. Time to buy?
- Motley Fool•12 days ago
3 Stocks That Turned $10,000 Into $1 Million
These three biotech stocks delivered monster returns over the past couple of decades. Here's how.
- Simply Wall St.•12 days ago
What Investors Should Know About Gilead Sciences Inc’s (NASDAQ:GILD) Financial Strength
Gilead Sciences Inc (NASDAQ:GILD), a large-cap worth US$85.05B, comes to mind for investors seeking a strong and reliable stock investment. Risk-averse investors who are attracted to diversified streams of revenueRead More...
- Motley Fool•12 days ago
Why Sangamo Therapeutics Stock Dropped Today
Valuing early-stage biotechs is hard.
- Reuters•13 days ago
UK biotech firm Autolus joins CAR-T rush with Nasdaq IPO filing
Autolus Therapeutics, a small British company developing cell therapy treatments, is to join the swelling ranks of listed biotech companies using the new anti-cancer technology with a planned IPO on Nasdaq. The group said on Tuesday it had filed a registration statement with the U.S. Securities and Exchange Commission for a proposed initial public offering (IPO) under the ticker symbol AUTL. The number of its American depositary shares to be sold in the IPO and the pricing terms have not yet been determined.
- CNBC Videos•9 days ago
Final Trade: IBB, GILD & more
The "Fast Money" traders share their final trades of the day, including Ethereum, Match, the IBB and Gilead.
- CNBC Videos•9 days ago
You should know the cost of a drug or procedure before it...
Sen. Bill Cassidy (R-La.) discusses Trump's plan to lower drug prices.
